Potential Mechanisms for Chemotherapy-Induced Impairments in Cognitive Function

Catherine E. Jansen

Christine Miaskowski

Marylin Dodd

Glenna Dowling

Joel Kramer

ONF 2006, 32(6), 1151-1163. DOI: 10.1188/05.ONF.1151-1163

Purpose/Objectives: To review the domains of cognitive function and their corresponding neuroanatomic structures as well as present current evidence for neurotoxicity associated with specific chemotherapeutic agents and potential mechanisms for chemotherapy-induced cognitive impairments.

Jump to a section

    References

    Ahles, T.A., & Saykin, A.J. (2001). Cognitive effects of standard-dose chemotherapy in patients with cancer. Cancer Investigation, 19, 812-820.

    Ahles, T.A., Saykin, A.J., Furstenberg, C.T., Cole, B., Mott, L.A., Skalla, K., et al. (2002). Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. Journal of Clinical Oncology, 20, 485-493.

    Ahles, T.A., Saykin, A.J., Noll, W.W., Furstenberg, C.T., Guerin, S., Cole, B., et al. (2003). The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psycho-Oncology, 12, 612-619.

    Aley, K.O., Reichling, D.B., & Levine, J.D. (1996). Vincristine hyperalgesia in the rat: A model of painful vincristine neuropathy in humans. Neuroscience, 73, 259-265.

    Andrewes, D.G. (2001). Neuropsychology: From theory to practice. New York: Psychology Press.

    Authier, N., Fialip, J., Eschalier, A., & Coudore, F. (2000). Assessment of allodynia and hyperalgesia after cisplatin administration to rats. Neuroscience Letters, 291, 73-76.

    Baxter, M.G., & Chiba, A.A. (1999). Cognitive functions of the basal forebrain. Current Opinion in Neurobiology, 9, 178-183.

    Beard, C.M., Kokmen, E., O'Brien, P.C., Ania, B.J., & Melton, L.J., III. (1997). Risk of Alzheimer's disease among elderly patients with anemia: Population-based investigations in Olmsted County, Minnesota. Annals of Epidemiology, 7, 219-224.

    Beck, W.T., & Kuttesch, J.F. (1992). Neurological symptoms associated with cyclosporine plus doxorubicin. Lancet, 340, 496.

    Blumenfeld, H. (2002). Neuroanatomy through clinical cases. Sunderland, MA: Sinauer Associates.

    Brezden, C.B., Phillips, K.A., Abdolell, M., Bunston, T., & Tannock, I.F. (2000). Cognitive function in breast cancer patients receiving adjuvant chemotherapy. Journal of Clinical Oncology, 18, 2695-2701.

    Brown, K.A., Esper, P., Kelleher, L.O., O'Neill, J.E.B., Polovich, M., & White, J.M. (2001). Chemotherapy and biotherapy guidelines and recommendations for practice. Pittsburgh, PA: Oncology Nursing Society.

    Chabner, B.A., & Longo, D.L. (2001). Cancer chemotherapy and biotherapy: Principles and practice (3rd ed.). Philadelphia: Lippincott Williams and Wilkins.

    Chiarelli, A.M., Marrett, L.D., & Darlington, G. (1999). Early menopause and infertility in females after treatment for childhood cancer diagnosed in 1964-1988 in Ontario, Canada. American Journal of Epidemiology, 50, 245-254.

    Choi, S.M., Lee, S.H., Yang, Y.S., Kim, B.C., Kim, M.K., & Cho, K.H. (2001). 5-fluorouracil-induced leukoencephalopathy in patients with breast cancer. Journal of Korean Medical Science, 16, 328-334.

    Cleeland, C.S., Bennett, G.J., Dantzer, R., Dougherty, P.M., Dunn, A.J., Myers, C.A., et al. (2003). Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer, 97, 2919-2925.

    Cohen, Y., Lossos, A., & Polliack, A. (2002). Neurotoxicity with leukoencephalopathy after a single intravenous high dose of methotrexate in a patient with lymphoma. Acta Haematologica, 107, 185-186.

    Cossaart, N., SantaCruz, K.S., Preston, D., Johnson, P., & Skikne, B.S. (2003). Fatal chemotherapy-induced encephalopathy following high-dose therapy for metastatic breast cancer: A case report and review of the literature. Bone Marrow Transplantation, 31, 57-60.

    Cull, A., Hay, C., Love, S.B., Mackie, M., Smets, E., & Stewart, M. (1996). What do cancer patients mean when they complain of concentration and memory problems? British Journal of Cancer, 74, 1674-1679.

    Cunningham, R.S. (2003). Anemia in the oncology patient. Cognitive function and cancer. Cancer Nursing, 26(6, Suppl.), 38S-42S.

    Cutter, W.J., Norbury, R., & Murphy, D.G. (2003). Oestrogen, brain function, and neuropsychiatric disorders. Journal of Neurology, Neurosurgery, and Psychiatry, 74, 837-840.

    Dantzer, R. (2001). Cytokine-induced sickness behavior: Where do we stand? Brain, Behavior, and Immunity, 15, 7-24.

    Dnistrian, A.M., Schwartz, M.K., Fracchia, A.A., Kaufman, R.J., Hakes, T.B., & Currie, V.E. (1983). Endocrine consequences of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patients. Cancer, 51, 803-807.

    Dorr, R.T., & Von Hoff, D.D. (Eds.). (1994). Cancer chemotherapy handbook (2nd ed.). Norwalk, CT: Appleton and Lange.

    Egorin, M.J., Kaplan, R.S., Salcman, M., Aisner, J., Colvin, M., Wiernik, P.H., et al. (1982). Cyclophosphamide plasma and cerebrospinal fluid kinetics with and without dimethyl sulfoxide. Clinical Pharmacology and Therapuetics, 32, 122-128.

    Erlanger, D.M., Kutner, K.C., & Jacobs, A.R. (1999). Hormones and cognition: Current concepts and issues in neuropsychology. Neuropsychology Review, 9, 175-207.

    Everitt, B.J., & Robbins, T.W. (1997). Central cholinergic systems and cognition. Annual Review of Psychology, 48, 649-684.

    Filley, C.M. (1998). The behavioral neurology of cerebral white matter. Neurology, 50, 1535-1540.

    Filley, C.M. (1999). Toxic leukoencephalopathy. Clinical Neuropharmacology, 22, 249-260.

    Filley, C.M. (2000). Clinical neurology and executive dysfunction. Seminars in Speech and Language, 21, 95-108.

    Filley, C.M. (2001). The behavioral neurology of white matter. New York: Oxford University Press.

    Filley, C.M. (2002). The neuroanatomy of attention. Seminars in Speech and Language, 23, 89-98.

    Filley, C.M., & Kleinschmidt-DeMasters, B.K. (2001). Toxic leukoencephalopathy. New England Journal of Medicine, 345, 425-432.

    Freeman, J.R., & Broshek, D.K. (2002). Assessing cognitive dysfunction in breast cancer: What are the tools? Clinical Breast Cancer, 3(Suppl. 3), S91-S99.

    Gazzaniga, M.S., Ivry, R.B., & Mangun, G.R. (2002). Cognitive neuroscience: The biology of the mind (2nd ed.). New York: Norton.

    Genvresse, I., Dietzmann, A., Massenkeil, G., Spath-Schwalbe, E., & Possinger, K. (1999). Subacute encephalopathy after combination chemotherapy including moderate-dose methotrexate in a patient with gastric cancer. Anti-Cancer Drugs, 10, 293-294.

    Glaspy, J. (1997). The impact of epoetin alfa on quality of life during cancer chemotherapy: A fresh look at an old problem. Seminars in Hematology, 34(3, Suppl. 2), 20-26.

    Gordon, M.S. (2002). Managing anemia in the cancer patient: Old problems, future solutions. Oncologist, 7, 331-341.

    Greenwald, E.S. (1976). Organic mental changes with fluorouracil therapy [Letter]. JAMA, 235, 248-249.

    Grober, S.E. (2002). Resources for treatment of chemotherapy-related cognitive difficulty. Cancer Practice, 10, 216-218.

    Groopman, J.E., & Itri, L.M. (1999). Chemotherapy-induced anemia in adults: Incidence and treatment. Journal of the National Cancer Institute, 91, 1616-1634.

    Groth-Marnat, G. (Ed.). (2000). Neuropsychological assessment in clinical practice. New York: Wiley.

    Haan, M.N., Shemanski, L., Jagust, W.J., Manolio, T.A., & Kuller, L. (1999). The role of APOE epsilon 4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA, 282, 40-46.

    Hopkins, S.J., & Rothwell, N.J. (1995). Cytokines and the nervous system. I: Expression and recognition. Trends in Neuroscience, 18, 83-88.

    Jacobs, D.M., Tang, M.X., Stern, Y., Sano, M., Marder, K., Bell, K.L., et al. (1998). Cognitive function in nondemented older women who took estrogen after menopause. Neurology, 50, 368-373.

    Kaasa, S., Olsnes, B.T., & Mastekaasa, A. (1988). Neuropsychological evaluation of patients with inoperable non-small cell lung cancer treated with combination chemotherapy or radiotherapy. Acta Oncologica, 27, 241-246.

    Kaplan, H.S. (1992). A neglected issue: The sexual side effects of current treatments for breast cancer. Journal of Sex and Marital Therapy, 18, 3-19.

    Kaplan, R.S., & Wiernik, P.H. (1982). Neurotoxicity of antineoplastic drugs. Seminars in Oncology, 9, 103-130.

    Keime-Guibert, F., Napolitano, M., & Delattre, J.Y. (1998). Neurological complications of radiotherapy and chemotherapy. Journal of Neurology, 245, 695-708.

    Kiu, M.C., Liaw, C.C., Yang, T.S., Lai, G.M., Hsi, S.N., & Lu, C.S. (1994). Transient neurological disturbances induced by the chemotherapy of high-dose methotrexate for osteogenic sarcoma. Anti-Cancer Drugs, 5, 480-482.

    Knobf, M.T. (1998). Natural menopause and ovarian toxicity associated with breast cancer therapy. Oncology Nursing Forum, 25, 1519-1530.

    Kronfol, Z., & Remick, D.G. (2000). Cytokines and the brain: Implications for clinical psychiatry. American Journal of Psychiatry, 157, 683-694.

    Laterra, J., & Goldstein, G.W. (2000). Ventricular organization of cerebrospinal fluid: Blood-brain barrier, brain edema, and hydrocephalus. In E.R. Kandel, J.H. Schwartz, & T.M. Jessell (Eds.), Principles of neural science (4th ed., pp. 1288-1301). New York: McGraw-Hill.

    Lee, Y.Y., Nauert, C., & Glass, J.P. (1986). Treatment-related white matter changes in cancer patients. Cancer, 57, 1473-1482.

    Lezak, M.D., Howieson, D.B., & Loring, D.W. (2004). Neuropsychological assessment (4th ed.). New York: Oxford University Press.

    Ludwig, H. (1999). Epoetin in cancer-related anaemia. Nephrology, Dialysis, Transplantation, 14(Suppl. 2), 85-92.

    Maier, S.F. (2003). Bi-directional immune-brain communication: Implications for understanding stress, pain, and cognition. Brain, Behavior, and Immunity, 17, 69-85.

    Maier, S.F., & Watkins, L.R. (1998). Cytokines for psychologists: Implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychological Review, 105, 83-107.

    Maier, S.F., & Watkins, L.R. (2003). Immune-to-central nervous system communication and its role in modulating pain and cognition: Implications for cancer and cancer treatment. Brain, Behavior, and Immunity, 17(Suppl. 1), S125-S131.

    Maki, P., & Hogervost, E. (2003). HRT and cognitive decline. Best Practice and Research: Clinical Endocrinology and Metabolism, 17, 105-122.

    McEwen, B.S., Alves, S.E., Bulloch, K., & Weiland, N.G. (1997). Ovarian steroids and the brain: Implications for cognition and aging. Neurology, 48(5, Suppl. 7), S8-S15.

    Means, R.T., Jr. (1999). Advances in the anemia of chronic disease. International Journal of Hematology, 70, 7-12.

    Meirow, D. (2000). Reproduction post-chemotherapy in young cancer patients. Molecular and Cellular Endocrinology, 169, 123-131.

    Meyers, C.A. (2000). Neurocognitive dysfunction in cancer patients. Oncology, 14, 75-79.

    Meyers, C.A., Byrne, K.S., & Komaki, R. (1995). Cognitive deficits in patients with small cell lung cancer before and after chemotherapy. Lung Cancer, 12, 231-235.

    Meyers, C.A., & Scheibel, R.S. (1990). Early detection and diagnosis of neurobehavioral disorders associated with cancer and its treatment. Oncology, 4, 115-122.

    Milward, E.A., Grayson, D.A., Creasey, H., Janu, M.R., Brooks, W.S., & Broe, G.A. (1999). Evidence for association of anaemia with vascular dementia. Neuroreport, 10, 2377-2381.

    Mizutani, T., Morimatsu, Y., & Hayakawa, K. (1984). Necrotizing leuko-encephalopathy and treated multiple myeloma. An autopsy case without intrathecal chemotherapy or irradiation of the brain. Acta Pathologica Japonica, 34, 655-662.

    Moore, D. (2003). Toxic leukoencephalopathy: A review and report of two chemotherapy-related cases. Clinical Journal of Oncology Nursing, 7, 413-417.

    Neuwelt, E.A., Pagel, M., Barnett, P., Glassberg, M., & Frenkel, E.P. (1981). Pharmacology and toxicity of intracarotid adriamycin administration following osmotic blood-brain barrier modification. Cancer Research, 41(11, Pt. 1), 4466-4470.

    Nieto, Y., Cagnoni, P.J., Bearman, S.I., Shpall, E.J., Matthes, S., DeBoom, T., et al. (1999). Acute encephalopathy: A new toxicity associated with high-dose paclitaxel. Clinical Cancer Research, 5, 501-506.

    Niiya, M., Niiya, K., Kiguchi, T., Shibakura, M., Asaumi, N., Shinagawa, K., et al. (2003). Induction of TNF-alpha, uPA, IL-8 and MCP-1 by doxorubicin in human lung carcinoma cells. Cancer Chemotherapy and Pharmacology, 52, 391-398.

    Nolte, J. (2002). The human brain: An introduction to its functional anatomy (5th ed.). St. Louis, MO: Mosby.

    Olin, J.J. (2001). Cognitive function after systemic therapy for breast cancer. Oncology, 15, 613-618.

    Oxman, T.E., & Silberfarb, P.M. (1980). Serial cognitive testing in cancer patients receiving chemotherapy. American Journal of Psychiatry, 137, 1263-1265.

    Padmanabhan, N., Wang, D.Y., Moore, J.W., & Rubens, R.D. (1987). Ovarian function and adjuvant chemotherapy for early breast cancer. European Journal of Cancer and Clinical Oncology, 23, 745-748.

    Perry, M.C. (2001). The chemotherapy source book (3rd ed.). Philadelphia: Lippincott Williams and Wilkins.

    Peterson, L.G., & Popkin, M.K. (1980). Neuropsychiatric effects of chemotherapeutic agents for cancer. Psychosomatics, 21, 141-153.

    Pollmacher, T., Haack, M., Schuld, A., Reichenberg, A., & Yirmiya, R. (2002). Low levels of circulating inflammatory cytokines—Do they affect human brain functions? Brain, Behavior, and Immunity, 16, 525-532.

    Polomano, R.C., Mannes, A.J., Clark, U.S., & Bennett, G.J. (2001). A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain, 94, 293-304.

    Poniatowski, B.C., Grimm, P., & Cohen, G. (2001). Chemotherapy-induced menopause: A literature review. Cancer Investigation, 19, 641-648.

    Posner, J.B. (1995). Neurologic complications of cancer. Philadelphia: F.A. Davis.

    Ryan, C.M., Morrow, L.A., Bromet, E.J., & Parkinson, D.K. (1987). Assessment of neuropsychological dysfunction in the workplace: Normative data from the Pittsburgh Occupational Exposures Test Battery. Journal of Clinical and Experimental Neuropsychology, 9, 665-679.

    Saarto, T., Blomqvist, C., Valimaki, M., Makela, P., Sarna, S., & Elomaa, I. (1997). Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in pre-menopausal breast cancer patients. Journal of Clinical Oncology, 15, 1341-1347.

    Saykin, A.J., Ahles, T.A., & McDonald, B.C. (2003). Mechanisms of chemotherapy-induced cognitive disorders: Neuropsychological, patho-physiological, and neuroimaging perspectives. Seminars in Clinical Neuropsychiatry, 8, 201-216.

    Schagen, S.B., Muller, M.J., Boogerd, W., Rosenbrand, R.M., van Rhijn, D., Rodenhuis, S., et al. (2002). Late effects of adjuvant chemotherapy on cognitive function: A follow-up study in breast cancer patients. Annals of Oncology, 13, 1387-1397.

    Schagen, S.B., Muller, M.J., Boogerd, W., & van Dam, F.S. (2002). Cognitive dysfunction and chemotherapy: Neuropsychological findings in perspective. Clinical Breast Cancer, 3(Suppl. 3), S100-S108.

    Schagen, S.B., van Dam, F.S., Muller, M.J., Boogerd, W., Lindeboom, J., & Bruning, P.F. (1999). Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer, 85, 640-650.

    Schobitz, B., de Kloet, E.R., & Holsboer, F. (1994). Gene expression and function of interleukin 1, interleukin 6 and tumor necrosis factor in the brain. Progress in Neurobiology, 44, 397-432.

    Servaes, P., Verhagen, C.A., & Bleijenberg, G. (2002). Relations between fatigue, neuropsychological functioning, and physical activity after treatment for breast carcinoma: Daily self-report and objective behavior. Cancer, 95, 2017-2026.

    Shapiro, C., & Henderson, C. (1994). Adjuvant therapy of breast cancer. Hematology/Oncology Clinics of North America, 8, 213-231.

    Sherwin, B.B. (1996). Hormones, mood, and cognitive functioning in post-menopausal women. Obstetrics and Gynecology, 87(2, Suppl.), 20S-26S.

    Sherwin, B.B. (1998). Estrogen and cognitive functioning in women. Proceedings of the Society for Experimental Biology and Medicine, 217, 17-22.

    Shilling, V., Jenkins, V., Fallowfield, L., & Howell, A. (2001). The effects of oestrogens and anti-oestrogens on cognition. Breast, 10, 484-491.

    Silberfarb, P.M., Philibert, D., & Levine, P.M. (1980). Psychosocial aspects of neoplastic disease: II. Affective and cognitive effects of chemotherapy in cancer patients. American Journal of Psychiatry, 137, 597-601.

    Spreen, O., & Strauss, E. (1998). A compendium of neuropsychological tests (2nd ed.). New York: Oxford University Press.

    Squire, L.R. (1987). Memory and the brain. New York: Oxford University Press.

    Stivelman, J.C. (2000). Benefits of anaemia treatment on cognitive function. Nephrology, Dialysis, Transplantation, 15(Suppl. 3), 29-35.

    Takimoto, C.H., Lu, Z.H., Zhang, R., Liang, M.D., Larson, L.V., Cantilena, L.R., Jr., et al. (1996). Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrognease deficiency. Clinical Cancer Research, 2, 477-481.

    Tchen, N., Juffs, H.G., Downie, F.P., Yi, Q.L., Hu, H., Chemerynsky, I., et al. (2003). Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology, 21, 4175-4183.

    Troy, L., McFarland, K., Littman-Power, S., Kelly, B.J., Walpole, E.T., Wyld, D., et al. (2000). Cisplatin-based therapy: A neurological and neuropsychological review. Psycho-Oncology, 9, 29-39.

    Tuxen, M.K., & Hansen, S.W. (1994). Neurotoxicity secondary to antineoplastic drugs. Cancer Treatment Reviews, 20, 191-214.

    van Dam, F.S., Schagen, S.B., Muller, M.J., Boogerd, W., Wall, E.v.d., Droogleever Fortuyn, M.E., et al. (1998). Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. Journal of the National Cancer Institute, 90, 210-218.

    Vanderploeg, R.D. (2000). Clinician's guide to neuropsychological assessment (2nd ed.). Mahwah, NJ: Lawrence Erlbaum Associates.

    Verstappen, C.C., Heimans, J.J., Hoekman, K., & Postma, T.J. (2003). Neurotoxic complications of chemotherapy in patients with cancer: Clinical signs and optimal management. Drugs, 63, 1549-1563.

    Wefel, J.S., Lenzi, R., Theriault, R.L., Davis, R.N., & Meyers, C.A. (2004). The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: Results of a prospective, randomized, longitudinal trial. Cancer, 100, 2292-2299.

    Wichmann, M.W., Meyer, G., Adam, M., Hochtlen-Vollmar, W., Angele, M.K., Schalhorn, A., et al. (2003). Detrimental immunologic effects of preoperative chemoradiotherapy in advanced rectal cancer. Diseases of the Colon and Rectum, 46, 875-887.

    Wieneke, M.M., & Dienst, E.R. (1995). Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psycho-Oncology, 4, 61-66.

    Wilson, C.J., Finch, C.E., & Cohen, H.J. (2002). Cytokines and cognition—The case for a head-to-toe inflammatory paradigm. Journal of the American Geriatrics Society, 50, 2041-2056.

    Yaffe, K., Cauley, J., Sands, L., & Browner, W. (1997). Apolipoprotein E phenotype and cognitive decline in a prospective study of elderly community women. Archives of Neurology, 54, 1110-1114.

    Zaks-Zilberman, M., Zaks, T.Z., & Vogel, S.N. (2001). Induction of proin-flammatory and chemokine genes by lipopolysaccharide and paclitaxel (Taxol™) in murine and human breast cancer cell lines. Cytokine, 15, 156-165.